Disclosures: Natalie Commins: Nothing to Disclose, Rohit Gupta: Nothing to Disclose, Andrew Sloss: Nothing to Disclose, Tehara Wickremeratne: Nothing to Disclose, Roger Wilson: Nothing to Disclose, Jonathan Langton: Nothing to Disclose, Brooke Gaggin: Nothing to Disclose, James O'Beirne: CSL Behring: Advisor, ROCHE: Advisor, Novo Nordisk: Advisor 1944 RELATIONSHIP BETWEEN IMMUNE CELL INFILTRATION AND OUTCOMES IN CHOLANGIOCARCINOMA Keiko Iwaisako 1 Hiroaki Fuji 2 Momoko Fujita 3 Reina Sawabu 3 Shoko Tsukamoto 4 Masaki Yamamoto 5 Ryo Tofukuji 5 Masataka Asagiri 6 Daichi Nakamura 7 Keisuke Okura 7 Takahiro Nishio 8 , 1 Doshisha University and Graduate School of Medicine, Kyoto University, 2 Hyogo Medical University, 3 Faculty of Life and Medical Sciences, Doshisha University, 4 The Graduate School of Biostudies, Kyoto University, 5 Graduate School of Life and Medical Sciences, Doshisha University, 6 Yamaguchi University Graduate School of Medicine, 7 Graduate School of Medicine, Kyoto University, 8 Kyoto University Background: Among primary liver cancers, hepatocellular carcinoma (HCC) resulting from chronic viral hepatitis is declining in developed countries due to advances in clinical management, while the number of patients with intrahepatic cholangiocarcinoma (ICC) is increasing
Highly concentrated sterile Artichoke Extract formula professional quality
Although, there were significant differences in CAT activity between groups at baseline which may have confounded these results
hLB-001 dosing All participants received the planned hLB-001 dose of 5.0 10 13 vg/kg via intravenous (IV) infusion
